Fifty patients with intermediate-or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age from 16 t o 60 years (median 42 years). All patients received dexamethasone, high-dose cytarabine, and cisplatin (DHAP) for two courses at 3-t o 4-week intervals. Patients achieving a partial or complete response were scheduled t o receive involved-field radiotherapy and highdose carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (ABMT). Among 48 evaluable patients (ie, 1 was lost t o follow-up and 1 had no measurable disease) 7 patients obtained a complete response (CR) and another 21 patients achieved partial response (PR), whereas the remaining 20 patients failed. One responder died of treatment-related toxicity, and six others declined ABMT. The patient with no ATIENTS WITH advanced diffuse non-Hodgkin's lym-P phoma (NHL) are rarely cured of their disease after conventional chemotherapy fails,' but experience gained in Burkitt's lymphoma has shown that these lymphomas may still be sensitive to intensive chemoradiotherapy after failing conventional
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With bone marrow transplantation (BMT) providing hematologic support, administering intensive chemoradiotherapy and to cure some children or adults with disseminated aggressive NHL has been p~ssible. ' .~.~' The appropriate place for high-dose chemoradiotherapy and BMT between front line and relapse has not yet been determined, despite encouraging results in numerous pilot Several groups of investigators using ABMT have suggested that response to preceding therapy may have prognostic importance in the outcome of ABMT in patients who have relapsed,"," and confirmation of these findings was the major achievement of the 100-patient retrospective analysis reported in 1987?
In 1986, an international multicentric study group called PARMA was organized, involving BMT centers from around the world, with the objective of testing the value of ABMT for patients with relapsed lymphoma in a prospective, randomized trial.30 We review the pilot study of the PARMA protocol, which was performed in 1986 and 1987. We wished to confirm the response rate of the DHAF' regimen3' in patients with relapsed lymphoma, pilot the new conditioning regimen of involved-field radiotherapy and BEAC, and confirm the retrospective analysisz9 in a prospective international ~t u d y .~"
MATERIALS AND METHODS
Fifty patients aged 16 to 60 years at first relapse of intermediate (28 patients) measurable disease did not progress on DHAP and was submitted t o ABMT. Twenty-two patients underwent ABMT [20 with BEAC and 2 with cyclophosphamide plus total body irradiation (TBI)] of whom 2 (9%) died of toxicity and 10 relapsed. One patient was a suicide at 28 months post-ABMT in CCR and 9 are alive disease-free 24 months to 32 months (median 30 months) post-ABMT. The actuarial 2-year eventfree survival for patients undergoing transplantation is 40%. This prospective multicenter trial documents the ability of DHAP followed by ABMT t o produce durable complete remission in a significant proportion of patients with relapsed aggressive NHL. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT and 20% of the total group are projected t o be long-term disease-free survivors. 6 Table 1 .
Methods. All patients were submitted to the DHAP regimen as reported by Velasquez et al." After course 1 of DHAP, with the exception of clearly progressive disease (n = 14), BM was harvested under general anesthesia and frozen as previously described4.' unless the marrow had been stored previously. All patients had normal BM biopsies at time of harvest. A second course of DHAP was given beginning 1 day after harvest. At day 20 after second DHAP, patients were restaged according to previous involved sites of disease at initiation of study. CR was defined as complete disappearance of all previously involved sites. Partial response (PR) was defined as at least 50% reduction of all previously involved sites with no new lesion. CR and PR were defined as sensitive relapses and eligible for autologous BMT (ABMT).
Patients who had shown a response were then included in an involved-field radiotherapy (if bulky disease was present at relapse) and BEAC protocol (all patients) as shown in Table 2 (two patients previously irradiated at site of bulky disease did not receive radiotherapy according to the PARMA protocol). Two were grafted with cyclophosphamide and total body irradiation (TBI) as reported by the Seattle by individual patient decision with the authorization of the chairman and seven were not grafted (one toxic death, six refusals). ABMT was performed as previously reported?' Histologic material was reviewed centrally by a reference pathologist (D.W.) using the working formulation for classification of NHL.3Z
Statistical method. Comparisons of categorical data were performed using the chi-square and Ficher's exact test. Survival curves were computed according to the method of Kaplan-Meier. An event was defined as a relapse, evidence of progression, or death whatever the cause. In the event-free survival curve, the date of the first event is taken into account.
RESULTS
Forty-eight patients are evaluable. One was in complete remission before DHAP (complete surgical excision), and one was lost to follow-up. The seven other responders were not grafted because of toxic death (n = 1) or individual decision (n = 6). One refused treatment and died. Five had received four to six additional courses of DHAP. None of them are alive disease-free at present (one is still alive but has progressive disease).
DISCUSSION
High-dose therapy and AJ3MT can cure patients with relapsed, aggressive NHL.2-22 The results of this prospective multicenter pilot study provide the only available prospective data for estimation of the impact of this treatment approach on such patients. Fifty-eight percent of all patients treated consecutively in this study after relapse from an Adriamycin-containing induction regimen were chemotherapy sensitive and thus represented good-risk patients for ABMT. Two percent (1 of 50) of the patients for whom this strategy was intended died of treatment-related toxicity from the DHAP, however, and 20% (6 of 29) declined to undergo BMT despite a good response to conventional rescue therapy. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT, and 40% of these patients (ie, 20% of the total who entered the study) are projected to be long-term, disease-free survivors.
The 58% total response rate observed in this study confirms the original report by Velasquez et al on the activity of DHAP for relapsed lymphoma^.^' In both studies, a few of the responding patients actually achieved complete remissions. We found no difference in the response rate between intermediate-grade and high-grade lymphomas.
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